References
- Coca S, Enrech S, Moreno Garcia V, et al (2005). Evaluation of the antitumor activity of interleukin-12 in an experimental murine model of colorectal cancer induced by 1, 2 dimethylhydrazine (DMH). Rev Esp Enferm Dig, 97, 619-28.
- Cranmer LD, Trevor KT Hersh EM (2004). Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother, 53, 275-306. https://doi.org/10.1007/s00262-003-0432-5
- Dullaers M, Van Meirvenne S, Heirman C, et al (2006). Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther, 13, 630-40. https://doi.org/10.1038/sj.gt.3302697
- Fuss IJ, Kanof ME, Smith PD Zola H (2009). Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol Chapter, 7, Unit7 1.
- Garg NK, Dwivedi P, Prabha P Tyagi RK (2013). RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine, 31, 1141-56. https://doi.org/10.1016/j.vaccine.2012.12.027
- Gately MK, Desai BB, Wolitzky AG, et al (1991). Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol, 147, 874-82.
- Gherardi MM, Ramirez JC Esteban M (2000). Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol, 74, 6278-86. https://doi.org/10.1128/JVI.74.14.6278-6286.2000
- Guermonprez P, Valladeau J, Zitvogel L, Thery C Amigorena S (2002). Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol, 20, 621-67. https://doi.org/10.1146/annurev.immunol.20.100301.064828
- Han B, Zhong H, Fan X, et al (2006). [A primary study of immunotherapy with carcinoembryonic antigen peptidepulsed, autologous human cultured dendritic cells in patients with advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi, 9, 340-4.
- Hansen M, Hjorto GM, Donia M, et al (2013). Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine, 31, 639-46. https://doi.org/10.1016/j.vaccine.2012.11.053
- Hwang EC, Lim MS, Im CM, et al (2013). Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells. Scand J Immunol, 77, 117-24. https://doi.org/10.1111/sji.12007
- Janeway CA, Jr. Medzhitov R (2002). Innate immune recognition. Annu Rev Immunol, 20, 197-216. https://doi.org/10.1146/annurev.immunol.20.083001.084359
- Kaech SM Ahmed R (2003). Immunology. CD8 T cells remember with a little help. Science, 300, 263-5. https://doi.org/10.1126/science.1084511
- Kikuchi T, Akasaki Y, Irie M, et al (2001). Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother, 50, 337-44. https://doi.org/10.1007/s002620100205
- Koutsokera A, Kiagia M, Saif MW, Souliotis K Syrigos KN (2013). Nutrition Habits, Physical Activity, and Lung Cancer: An Authoritative Review. Clin Lung Cancer, 14, 342-50. https://doi.org/10.1016/j.cllc.2012.12.002
- Lesterhuis WJ, de Vries IJ, Adema GJ Punt CJ (2004). Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol, 15 Suppl 4, iv145-51.
- Li R, Zheng X, Popov I, et al (2012). Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med, 10, 19. https://doi.org/10.1186/1479-5876-10-19
- Marten A, Renoth S, Heinicke T, et al (2003). Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther, 14, 483-94. https://doi.org/10.1089/104303403321467243
- Mehrotra PT, Wu D, Crim JA, Mostowski HS Siegel JP (1993). Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol, 151, 2444-52.
- Nouri-Shirazi M, Banchereau J, Fay J Palucka K (2000). Dendritic cell based tumor vaccines. Immunol Lett, 74, 5-10. https://doi.org/10.1016/S0165-2478(00)00243-1
- Perroud MW, Jr., Honma HN, Barbeiro AS, et al (2011). Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res, 30, 65. https://doi.org/10.1186/1756-9966-30-65
- Picanco-Castro V, de Sousa Russo-Carbolante EM Tadeu Covas D (2012). Advances in lentiviral vectors: a patent review. Recent Pat DNA Gene Seq, 6, 82-90. https://doi.org/10.2174/187221512801327433
- Portielje JE, Gratama JW, van Ojik HH, Stoter G Kruit WH (2003). IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother, 52, 133-44.
- Ragde H, Cavanagh WA Tjoa BA (2004). Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol, 172, 2532-8. https://doi.org/10.1097/01.ju.0000144211.51111.e4
- Schuler G Romani N (1997). Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. Adv Exp Med Biol, 417, 7-13. https://doi.org/10.1007/978-1-4757-9966-8_2
- Seggewiss R Dunbar CE (2005). A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer. J Clin Invest, 115, 2064-7. https://doi.org/10.1172/JCI26041
- Song Z, Guo C, Li Y, et al (2012). Enhanced antitumor effects of a dendritic cell vaccine transfected with gastric cancer cell total RNA carrying the 4-1BBL gene in vitro. Exp Ther Med, 3, 319-23.
- Tamandani DM, Shekari M Suri V (2009). Interleukin-12 gene polymorphism and cervical cancer risk. Am J Clin Oncol, 32, 524-528. https://doi.org/10.1097/COC.0b013e318192519a
- Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L Pistello M (2013). Viral vectors: a look back and ahead on gene transfer technology. New Microbiol, 36, 1-22.
- Wang J, Zou ZH, Xia HL, et al (2012). Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One, 7, e32695. https://doi.org/10.1371/journal.pone.0032695
Cited by
- MAGED4 Expression in Glioma and Upregulation in Glioma Cell Lines with 5-Aza-2'-Deoxycytidine Treatment vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3495
- 5-Fluorouracil and Interleukin-2 Immunochemotherapy Enhances Immunogenicity of Non-Small Cell Lung Cancer A549 Cells through Upregulation of NKG2D Ligands vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4039
- Adoptive Immunotherapy for Small Cell Lung Cancer by Expanded Activated Autologous Lymphocytes: a Retrospective Clinical Analysis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1487
- Tumor-derived CD4+CD25+ Tregs Inhibit the Maturation and Antigen-Presenting Function of Dendritic Cells vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2665
- Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine vol.13, pp.4, 2016, https://doi.org/10.3892/mmr.2016.4964
- Viral gene therapy for breast cancer: progress and challenges vol.17, pp.8, 2017, https://doi.org/10.1080/14712598.2017.1338684
- The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome vol.45, pp.12, 2015, https://doi.org/10.1002/eji.201545559
- K9(C4H4FN2O2)2Nd(PW11O39)2·25H2O induces apoptosis in human lung cancer A549 cells vol.13, pp.3, 2016, https://doi.org/10.3892/ol.2016.5543
- SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma vol.144, pp.4, 2018, https://doi.org/10.1007/s00432-018-2584-x